Clinical trials on Minimal Change Disease

  • CT-EU-00111902

    Sparsentan treatment study for children with Kidney Diseases

    This study involves children with kidney diseases that lead to high levels of protein in the urine. These diseases include Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Vasculitis (IgAV), and Alport Syndrome (AS). The study will use a drug called Sparsentan, administered as an oral suspension or tablet.

    The goal is to determine if Sparsentan is safe and effective for these children. Participants will receive Sparsentan for 112 weeks, and their progress will be monitored to see if protein levels in their urine decrease and if their overall health improves. The study is open-label, meaning all participants will know they are receiving the drug.

    • Sparsentan
  • Exploring Vagus Nerve Stimulation for Children with Tough-to-Treat Nephrotic Syndrome

    We are excited to introduce a new study called the kidNEY-VNS trial, which is designed for children who are dealing with a tough condition known as steroid resistant nephrotic syndrome (SRNS). This condition can be challenging because the usual steroid treatments don’t work, and children often have to take other medications that can have unwanted side effects.

    In our search for better and safer treatments, we’re exploring a novel approach called transcutaneous auricular vagus nerve stimulation (taVNS). This method involves a gentle stimulation of the vagus nerve, which is a part of the body’s nervous system that can influence inflammation. The best part? It’s noninvasive, meaning it doesn’t require surgery or internal treatments, making it a potentially safe option for children.

    The kidNEY-VNS trial is a pilot study, which means it’s the first step in understanding how well taVNS works for children with SRNS. We’re looking to see if this treatment is easy to follow, tolerable, and if it shows promise in helping manage the condition. We’ll also be keeping an eye on how it affects certain markers of inflammation in the body.

    Here’s how it works: The study will include children aged 3 to 17 who have SRNS. Participants will be divided into two groups. One group will receive the real taVNS treatment, and the other group will receive a sham treatment, which is like a placebo. This will help us understand the true effects of taVNS. The treatment involves using a device for 5 minutes each day at home for 26 weeks, and we’ll check in regularly through both in-person and virtual visits.

    We understand that trying a new treatment can be a big decision, which is why we’re committed to monitoring the health and safety of all participants closely throughout the study. At the end of the study period, everyone will have the option to receive the active taVNS treatment if they wish.

    If you’re interested in exploring this new potential treatment option for SRNS, the kidNEY-VNS trial might be a great opportunity. We’re here to answer any questions you might have and to support you every step of the way.